182 related articles for article (PubMed ID: 8417245)
1. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
Chalfin DB; Holbein ME; Fein AM; Carlon GC
JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
[TBL] [Abstract][Full Text] [Related]
2. Projected impact of monoclonal anti-endotoxin antibody therapy.
Bates DW; Lee TH
Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
[TBL] [Abstract][Full Text] [Related]
3. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies to endotoxin in the management of sepsis.
Fang KC
West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
Schulman KA; Glick HA; Rubin H; Eisenberg JM
JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
[TBL] [Abstract][Full Text] [Related]
6. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
7. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
Badía X; Segú L; García Alonso F; Rovira J
Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of HA-1A treatment for patients with sepsis.
van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
[TBL] [Abstract][Full Text] [Related]
9. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
[TBL] [Abstract][Full Text] [Related]
10. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
Tebas P
Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
[No Abstract] [Full Text] [Related]
11. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
Linden PK; Angus DC; Chelluri L; Branch RA
J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
[TBL] [Abstract][Full Text] [Related]
12. The economic impact of HA-1A (Centoxin) against endotoxin.
Barriere SL
Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
[TBL] [Abstract][Full Text] [Related]
13. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
[TBL] [Abstract][Full Text] [Related]
14. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
Fink MP
Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
[TBL] [Abstract][Full Text] [Related]
16. Antibody to endotoxin in the treatment of gram-negative sepsis.
Schentag JJ
JAMA; 1992 May; 267(17):2326-7. PubMed ID: 1564766
[No Abstract] [Full Text] [Related]
17. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
Gorelick KJ; Chmel H
Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
[TBL] [Abstract][Full Text] [Related]
18. Role of immunomodulator therapy in sepsis.
Caplan ES
Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and function after suspected gram-negative sepsis.
Perl TM; Dvorak L; Hwang T; Wenzel RP
JAMA; 1995 Jul; 274(4):338-45. PubMed ID: 7609265
[TBL] [Abstract][Full Text] [Related]
20. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis.
Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ
Crit Care Med; 1992 Jun; 20(6):730-5. PubMed ID: 1597023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
